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SuMMAry – After radical prostatectomy (rP), up to 60% of patients with high-risk prostate 
cancer (PC), such as high Gleason score, extracapsular prostatic extension (eCe), positive margins, 
seminal vesicle involvement (Svi), will develop biochemical relapse and they will require further local 
treatment. radiotherapy (rt) to the prostate bed has been used as adjuvant (Art) or salvage (Srt). 
in patients with high-risk PC, radiotherapy immediately after rP or adjuvant radiotherapy may erad-
icate residual localized microscopic disease and improve biochemical, progression-free survival, and 
overall survival. only a few observational studies have compared rP patients who have received only 
rt with patients who have received rt with some form of hormonal therapy. A few of them have 
reported improved progression-free survival with addition of hormonal therapy to Srt, but benefit in 
overall survival (oS) is not yet known.
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Three randomized controlled trials (rCts) have 
analyzed the effect of rt after radical prostatectomy. 
Primary outcomes in these trials have been different: 
clinical progression-free survival (cPFS), biochemical 
progression-free survival (bPFS) and metastases-free 
survival. it is of significance that a certain number of 
patients in the rt arms were treated with 60 Gray 
(Gy), which is less than currently used doses of 66 Gy 
and more. These trials have reported improvement in 
brFS in patients with high-risk pathological features, 
with the use of Art in comparison to observation 
only (1).
if radiation is conducted when PSA level is less than 
0,1 ng/ml within four months after rP it is called adju-
vant therapy. radiation usually starts after normaliza-
tion of urination. Salvage radiation therapy means ad-
ministration of rt to the prostatic bed in patients with 
biochemical recurrence (PSA level > 0.2 ng/ml).
eortC 22911 trial at median 10.6 years of follow-
up reported reduction in locoregional recurrence (8,4% 
in the Art group and 17,3% in the rP only group) (2).
eortC 2219 and SWoG 8794 showed im-
proved clinical PFS in patients with Art compared 
to rP only.
SWoG 8794 reported significantly improved oS 
in Art patients comparing with rP only, at more 
than 12 years of follow-up (74% vs 66%) (3). This trial 
also reported improved metastatic recurrence-free sur-
vival (mrFS) (71% for Art vs 61% for rP only).
in patients with positive surgical margins, these tri-
als demonstrated statistically significant improvement 
in brFS in men who received rt in comparison to 
rP only. These trials did not report difference in oS 
between two groups of patients.
in patients with GS 7-10, only one study demon-
strated significant improvement in brFS in patients 
who have received rt (4).
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SWoG 8794 at median 12,6 years of follow up 
demonstrated that 9 patients would need to be treated 
with Art after rP compared to rP only to prevent 
one death of any cause (5).
At same median of follow-up eortC 22911 doc-
umented that about 56 patients would need to be 
treated with Art after rP to prevent one case of 
death from PC compared to rP-only patients.
Few studies have demonstrated that Srt improves 
outcomes in patients with local or PSA recurrence 
compared to rP patients, but the benefit is not present 
in all groups of patients (6).
Adjuvant radiation therapy given to all high-risk 
patients will over-treat about 50% of patients who are 
cancer-free, exposing them to unnecessary toxicity and 
causing poorer quality of life.
Approximately 60% of high-risk patients with 
PSA recurrence after rP will develop metastatic dis-
ease if left untreated (7). 
if salvage radiation therapy is initiated at first sign 
of recurrence after rP, approximately 50% of patients 
will have long PSA response.
Many of prostate cancer patients if left untreated 
will not die from the disease and even those with bio-
chemical recurrence will not certainly become symp-
tomatic from the disease.
Discussion
it is always a question in high-risk post-rP pa-
tients when to administer rt - before or after bio-
chemical recurrence. Art may be given to a number 
of patients that would never experience recurrence. 
Srt could lead to metastatic disease because of later 
onset.
Many studies have shown that Art patients have 
better outcomes compared to Srt patients. in pa-
tients with Art rates of biochemical recurrence and 
metastasis are lower than in patients with Srt at sim-
ilar follow-up period. Cause specific survival (CSS) 
and oS are less clear. it is not well documented if Art 
leads to superior outcomes in the absence of random-
ization.
Srt and Art trials differ in numerous factors 
such as rt protocols (Art trials often used lower rt 
doses than Srt trials) and different techniques, fol-
low-up period, different pathological profile. despite 
various studies there is not enough clinical data to an-
swer the question if Art is superior to Srt. A recent 
trial at 5 years follow-up found no difference in brFS 
rates between pt3n0 patients (PSA ≤ 0.5 ng/ml) who 
have received Art in comparison to eSrt (9).
The study of Pfister et al. reported that outcomes are 
better when Srt is initiated at the lowest PSA values. 
Several studies have reported that, if pre-radiotherapy 
PSA is lower than 0,5 ng/ml, the biochemical relapse-
free survival can be improved (10). The term eSrt re-
fers to patients with undetectable PSA after prostatec-
tomy who have subsequent PSA rise ≤0.5 ng/ml. At 2 
years follow-up, Siegmann reported bPFS of 83% in 
patients with PSA ≤0.2 ng/ml at the time of Srt com-
pared to 61% when PSA is ≥0.28 to ≤1 ng/ml (11).
Jereczek-Fossa compared two groups of patients 
with 4 years of follow-up. one group received imme-
diate rt with PSA raising between 0.1 and 4 ng/ml 
vs. other group who received Srt >6 months after rP 
for biochemical recurrence lower than 13,7 ng/ml. 
Study reports that bPFS is significantly longer in the 
immediate rt group (79.8 vs. 60.5%). recent trials 
have reported that pre-radiotherapy PSA ≥0.2 ng/ml 
correlates with worse clinical outcome (12).
it is confirmed that the minimum radiation dose 
that should be delivered to the prostate bed is 64-65 
Gy (13).
one of the questions regarding the use of hormon-
al therapy in post-rP patients is when and for how 
long it should be administered.
in a study conducted by Parker et al., patients who 
have received Srt with bicalutamide (150 mg daily) 
had statistically significantly fewer number of metas-
tases and improved freedom from biochemical pro-
gression (14).
Some trials compared patients after radical prosta-
tectomy who received Art and patients who received 
Art+hormonal therapy (15). only one study has con-
firmed significant difference between these two groups. 
Bastide compared patients treated with Art + hor-
mone therapy vs Art alone and reported that hor-
mone therapy group had higher brFS rates (82,8% vs 
44,4%) (16).
As far as we know, early Adt reduces incidence of 
pathologic fractures and spinal cord compression and 
improves cancer-specific survival, but there is no ben-
efit in oS (17). 
rtoG 9601 has shown that survival was improved 
with Srt+ bicalutamide in most subgroups of patients 
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with positive surgical margins, PSA 0,7-4,0 ng/ml and 
GS 7, after a follow-up of 13 years. For now, the role of 
hormone therapy remains uncertain.
At 5 years follow-up GetuG-AFu 16 trial re-
ported that patients who were treated with Srt + gos-
erelin have improved progression-free survival espe-
cially those with postoperative PSA ≥ 0,2 ng/ml (18).
in conclusion, the 3 studies which included over 
1,110 patients reported that Art compared to watch 
and see strategy reduced the risk of PSA relapse by 20%.
The question of whether all patients with high-risk 
pathological features and without measurable PSA 
should undergo immediate Art or early Srt at bio-
chemical recurrence remains a subject of controversy.
Conclusion
Adjuvant radiotherapy for pathological t3n0M0 
prostate cancer significantly improves survival and re-
duces risk of distance metastases. Patients with locally 
advanced disease, positive margins and high GS are 
candidates for postoperative radiotherapy.
Art and eSrt seem to be equivalent in reducing 
the risk of biochemical recurrence (BCr), distant me-
tastases and death in pt3n0 patients.
There is significant impact of Art on brFS, but 
neither time to the onset of metastatic and hormone-
refractory disease nor prostate cancer specific and over-
all mortality differed significantly. For patients with 
only positive margins adjuvant radiotherapy is question-
able because only some patients will have BCr.
Art in comparison to observation prolongs bPFS, 
but its benefit in prolonging oS is questionable.
hormonal therapy should be offered to patients 
treated with salvage radiotherapy, especially to patients 
with postoperative PSA ≥ 0,2 ng/ml.
The role and length of Adt given with post-pros-
tatectomy irradiation remains unknown.
There are no published randomized clinical trials 
comparing Art and Srt. 
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Sažetak
KoJi Bi PACiJenti treBAli PriMiti rAdioterAPiJu  
u PoStoPerAtivnoM reCidivu BoleSti?
M. Matić i S. Matić
nakon radikalne prostatektomije (rP) više od 60% pacijenata s visokorizičnim patološkim pokazateljima, kao što su 
 visok Gleason score, ekstrakapsularno širenje, pozitivni rubovi, zahvaćeni sjemeni mjehurići, razviti će biokemijski relaps, te 
će zahtijevati daljnji lokalni tretman. radioterapija na ležište prostate može biti adjuvantna i (salvage) odgođena. Kod karci-
noma prostate visokog rizika, radioterapija odmah nakon rP ili adjuvantna radioterapija, može uništiti lokalnu rezidualnu 
mikroskopsku bolest i povezana je s poboljšanim biokemijskim preživljenjem do progresije bolesti i ukupnim preživljenjem. 
Malo je istraživanja koja su uspoređivala operirane pacijente koji su proveli zračenje ležišta prostate s pacijentima koji su uz 
rt primili i neku vrstu hormonske terapije. neka od njih su pokazala poboljšano preživljenje do progresije bolesti dodatkom 
hormonske terapije uz Srt, ali učinak na ukupno preživljenje je upitan.
Ključne riječi: radikalna prostatektomija, adjuvantna radioterapija, odgođena radioterapija
